Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
Express News | Halozyme Therapeutics Inc : Benchmark Raises Target Price to $75 From $60
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Halozyme Therapeutics Analyst Ratings
H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $65
H.C. Wainwright analyst Mitchell Kapoor maintains $Halozyme Therapeutics(HALO.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate
Express News | Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With Enhanze® for Multiple Types of Cancer
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With ENHANZE for Multiple Types of Cancer
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer
Even Though Halozyme Therapeutics (NASDAQ:HALO) Has Lost US$251m Market Cap in Last 7 Days, Shareholders Are Still up 271% Over 5 Years
Why Halozyme Therapeutics (HALO) Is a Top Momentum Stock for the Long-Term
Halozyme to Present at Upcoming Investor Conferences
Top 2 Health Care Stocks That May Plunge In August
Halozyme Therapeutics Insider Sold Shares Worth $1,228,020, According to a Recent SEC Filing
How Is The Market Feeling About Halozyme Therapeutics?
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
Halozyme Therapeutics Insider Sold Shares Worth $1,689,294, According to a Recent SEC Filing
Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO)